Back to Newsroom

StemCells, Inc.’s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada

NEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study™ is designed to assess the efficacy of the Company’s proprietary HuCNS-SC®platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord.

Click here to read more